OZN
- Product code
- OZN
- Device name
- C. Difficile Toxin Gene Amplification Assay
- Device class
- Class 2
- 21 CFR
- 21 CFR 866.3130
- Medical specialty
- Microbiology
- Marketing pathway
- 510(K)
- 510(k) clearances (last 3 years)
- 3
- Summaries archived here
- 3 (direct download)
- 510(k) clearances (all years, FDA)
- 18 (all years; only the last 3 years are listed here)
FDA classification definition
Amplification assay for the detection of c. Difficile toxin genes from stool specimens of symptomatic patients.
510(k) clearances, last 3 years (3)
| Number | Decision date | Applicant | Device name | Summary |
|---|---|---|---|---|
| K260045 | 2026-08-28 | Roche Molecular Systems, Inc. | cobas® Cdiff Nucleic acid test for use on the cobas®… | |
| K243730 | 2025-02-28 | Cepheid® | Xpert C. difficile/Epi | |
| K232092 | 2023-11-14 | Vela Operations USA | Great Basin Toxigenic C. difficile Direct Test (CDF2… |
Official FDA classification page: OZN
Classification and pathway per current FDA publications. Data from openFDA (CC0).